(Q36184798)

12 August 2017

1 reference

title

Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients (English)

1 reference

12 August 2017

Robert E Brown

1

1 reference

12 August 2017

1 June 2005

1 reference

Expert Review of Proteomics

12 August 2017

1 reference

12 August 2017

2

1 reference

12 August 2017

337-348

1 reference

12 August 2017

3

1 reference

Molecular markers for predicting response to tamoxifen in breast cancer patients

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Tamoxifen: a most unlikely pioneering medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Treatment of Langerhans cell histiocytosis with pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Interferon-alpha therapy, protein kinase C-alpha and Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Imatinib mesylate for cerebral Langerhans'-cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Mechanisms of resistance to rapamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Transactivation of the EGF receptor: is the PDGF receptor an unexpected accomplice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

A Ras activation pathway dependent on Syk phosphorylation of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U2OS cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Regulation of Wnt5a expression in human mammary cells by protein kinase C activity and the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Protein microarrays as a discovery tool for studying protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

NF-κB nuclear localization and its prognostic significance in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14789450.2.3.337

21 January 2018

Identifiers

DOI

10.1586/14789450.2.3.337

1 reference

12 August 2017

1 reference

PubMed ID

16000081